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Imaging targeted-agent
binding in vivo with two
probes
Brian W. Pogue,a,b,c, Kimberley S. Samkoe,a
Shannon Hextrum,a Julia A. O’Hara,a,b Michael Jermyn,a
Subhadra Srinivasan,a and Tayyaba Hasanc
a

Dartmouth College, Thayer School of Engineering, Hanover,
New Hampshire 03755
b
Dartmouth Medical School, Department of Surgery,
Department of Diagnostic Radiology, Lebanon,
New Hampshire 03756
c
Massachusetts General Hospital, Wellman Center for
Photomedicine, Boston, Massachusetts 02114

Abstract. An approach to quantitatively image targetedagent binding rate in vivo is demonstrated with dual-probe
injection of both targeted and nontargeted fluorescent
dyes. Images of a binding rate constant are created that
reveal lower than expected uptake of epidermal growth
factor in an orthotopic xenograft pancreas tumor 共2.3
⫻ 10−5 s−1兲, as compared to the normal pancreas 共3.4
⫻ 10−5 s−1兲. This approach allows noninvasive assessment of tumor receptor targeting in vivo to determine the
expected contrast, spatial localization, and efficacy in
therapeutic agent delivery. © 2010 Society of Photo-Optical Instru-

sion in vitro5 actually has lower EGF activity than the surrounding normal pancreas in vivo.
Most contrast agent imaging has been interpreted with a
simple pharmacokinetic model that is designed with as few
compartments and rate constants as possible to not overinterpret the data. A three compartment model 关Fig. 1共a兲兴 can be
used effectively to model targeted agent delivery in the tumor,
which includes compartments for 1. the concentration of drug
in the plasma within the vasculature, 2. the concentration in
the interstitial space of the tissue, and 3. the cellularassociated fraction of drug.7 The dominant fast rates in this
model are transvascular delivery of contrast agent through
rate constant K12, and then cell-associating rate constant due
to binding and uptake, K23. The dominant clearance from the
plasma is given by excretion mechanisms, such as those in the
liver and kidneys, through rate constant Ke. Then the slowest
rates tend to be those involved in backflow from the interstitial space to the vasculature K21, and from the cell-associated
space to the interstitial space K32. Each of these is shown in
the illustration of the model in Fig. 1共a兲.
Based on this linear model, and assuming that backflow
from interstitial space to vasculature K21 is negligible, the
concentrations are related to each other with first-order rate
equations:

mentation Engineers. 关DOI: 10.1117/1.3449109兴
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Targeting therapeutic drugs to tumors based on their overexpression of cellular receptors is widely researched and has
important clinical success.1,2 Yet there are essentially no good
tools to assess the in vivo receptor expression contrast between tumor as compared to normal surrounding tissue.3,4 In
tumors with very high molecular signaling such as in the
pancreas,4,5 it is not obvious when a particular receptor is
actually up-regulated as compared to the surrounding normal
tissue versus upregulated without biopsy. Imaging of receptor
status in vivo is problematic, because the majority of any targeted agent in vivo is often not cell-associated yet. Thus, any
single image simply provides a measure of the whole tissue
concentration rather than the bound concentration. Delivery
from the vascular supply to tumor cells requires transvascular
leakage, followed by diffusion through the interstitial space,
and binding to the targeted receptor followed by possible
internalization.6 As such, imaging concentration values in vivo
usually do not provide information about binding,7 since most
of the agent is in the interstitial space. In this work, we demonstrate a new methodology for quantitative imaging of effective binding rate in vivo, using the difference in fluorescence
signal between a targeted and untargeted agent. We use this to
demonstrate that a tumor known to have high EGFR expresAddress all correspondence to: Brian W. Pogue, Dartmouth College, Thayer
School of Engineering, 8000 Cummings Hall, Hanover, NH 03755. Tel: 603
646-3861; Fax: 603 646-3856; E-mail: brian.w.pogue@dartmouth.edu
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dC1
= − 共Ke + K12兲v1C1 + v2K21C2 ,
dt

共1兲

dC2
= + v1K12C1 − v2K23C2 + v3K32C3 ,
dt

共2兲

dC3
= + v2K23C2 − v3K32C3 .
dt

共3兲

v1

v3

Typical values of the concentrations are estimated by solving
Eqs. 共1兲–共3兲 in Fig. 1共b兲 using estimates of the K and v values
for the AsPC1 共pancreatic adenocarnioma兲 tumor. Using the
simplified compartment model from before, the cellassociation rate constant K23 can potentially be estimated
from the data of overall tissue concentration, given sufficient
accuracy and observables. The problem in accurately estimating K23 comes in the fact that the effect of K23 is a subtle part
of the overall curve, and it is not obvious that K12 and K23 can
be independently estimated given a single temporal dataset. In
fact, there is quite high sensitivity to K12, but considerably
less sensitivity to K23.
It is important to recognize that data from tissue does not
exactly discriminate the individual compartments C1, C2, and
C3 from each other, as the imaging yields the total signal
weighted by the relative volume fractions 共where each v is
normalized such that v P + vI + vC = 1兲. For a specific targeted
dye, which is planned to associate with the cellular fraction,
the total tissue concentration, CT is given by the volume fractions multiplied by the concentration of each:
1083-3668/2010/15共3兲/030513/3/$25.00 © 2010 SPIE
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Fig. 1 Compartment model is shown in 共a兲, which includes all the main components of the tumor, including vascular 共C1兲, interstitial 共C2兲, and
cellular-associated 共C3兲 concentrations. The rate constants from transitions are shown along with volume fractions. In 共b兲, an estimated table of
values is shown for the pancreas and AsPC-1 xenograft tumor 共K units are s−1兲. In 共c兲, the rate equations were solved and concentrations for each
compartment are plotted as a function of time. In 共d兲, the concentrations for targeted and nontargeted dyes are shown to illustrate what the imaging
data would show.

C T共 t 兲 = v 1C 1共 t 兲 + v 2C 2共 t 兲 + v 3C 3共 t 兲 .

共4兲

If a nonspecific imaging agent is used, it can be assumed that
the cellular associated fraction is equal to zero, such that only
plasma and interstitial fractions are seen and the tissue concentration is expressed by:

CNT共t兲 = v1C1共t兲 + v2C2共t兲 .

共5兲

These can be used along with the values of C1, C2, and C3
from before to estimate the expected bulk tissue concentrations, as shown in Fig. 1共d兲. In fact, the difference between
the CT and CNT values 关Fig. 1共d兲兴 appears very close to the
shape of the curve for the cellular-associated fraction 关Fig.
1共c兲兴.
Since the first term in each of these equations is low in the
regions where there are low plasma volume 共i.e., in bulk tissue without large vessels兲, then Eqs. 共4兲 and 共5兲 become:

C T共 t 兲 ⬇ v 2C 2共 t 兲 + v 3C 3共 t 兲 ,

共6兲

CNT共t兲 ⬇ v2C2共t兲 .

共7兲

Now from the rate model, some simple approximations can be
used to estimate a value for C3共t兲. Under the assumption that
K32 Ⰶ K23, the latter term in Eq. 共3兲 can be ignored, and then
C3共t兲 could be defined simply by integration as:

C 3共 t 兲 =

v2
K23
v3

冕

C2共t兲dt.

共8兲

These equations lead to the following derivation using the
observed data CT and CNT:

cT共t兲 − CNT共t兲
K23兰C2共t兲dt
v 3C 3
⬇
⬇
⬇ K23 . 共9兲
兰cNT共t兲dt
兰C2共t兲dt
v2兰C2共t兲dt
Therefore, an estimate of the binding rate constant K23 in vivo
is possible given the signal processing on the left side of Eq.
共9兲. Additionally, the observation that the difference between
the targeted and nontargeted concentrations 关Fig. 1共d兲兴 looks
qualitatively like the cellular-associated fraction 关Fig. 1共c兲兴
makes sense, since this is the numerator in this new Eq. 共9兲.
This nearly linear relationship means that imaging data can
be used to estimate binding, if two dyes can be injected at the
same time, and their fluorescence values used to calculate the
Journal of Biomedical Optics

ratio in Eq. 共9兲. To reiterate, the key assumption here is that
the vascular space effect on the signal is minimal, and the
backflow K32 is minimal. This first assumption means that this
approximation will not hold where there are large plasma regions in images, but when volume averaged data are used and
the v1 is low, this approximation should be valid.
The theoretical derivation in Eq. 共9兲 is in terms of the
concentrations of CT共t兲 and CNT共t兲, which are not directly
measured. Instead, fluorescence is used, which is linearly proportional to them. In this dual-probe imaging, a key issue is to
normalize for the difference in signal between the targeted
and non targeted dye fluorescence values. As such, we introduce the following approximations, FNT共t兲 = ANTCNT共t兲 and
FT共t兲 = ATCT共t兲, such that we can rewrite Eq. 共9兲 in terms of
the fluorescence intensity values:

BFT共t兲 − FNT共t兲
⬇ K23 ,
兰FNT共t兲dt

共10兲

where B is defined as B = ANT / AT, the ratio of amplitude values that accounts for excitation/emission differences in the
two agents as well as any collection efficiencies that are
geometry-specific to the imaging system. This ratio therefore
allows for cancellation of geometric/intensity effects that are
common to both agent signals, and can be estimated by sampling signals from normal tissue. The estimate of K23 from
Eq. 共10兲 can be done at any time point, so it is possible to get
multiple estimates as a function of time. But simulations and
data indicate that the estimate of K23 converges to a value
near 1 h in our case when a significant faction of the targeted
dye is bound, allowing accurate difference estimation in the
numerator.
To test the ability to image K23 directly, AsPC1 xenograft
pancreas tumors were inoculated into mice and imaged in
vivo. The tumors were used when they were a few millimeters
in diameter, and an incision was created in the abdomen and
the pancreas exposed for fluorescence imaging. The targeted
agent used was epidermal growth factor 共EGF兲 tagged with
IRDye800CW 共LI-COR Biosciences, Lincoln, Nebraska兲, and
the nonspecific agent was IRDye700DX by itself. The mice
were intravenously injected with a mixture containing 1 nmol
of each dye 共1.3 mM兲, and imaging was carried out on a
dual-channel flatbed fluorescence scanner 共Odyssey IR Imaging System, LI-COR Biosciences, Lincoln, Nebraska兲, which
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Fig. 2 The time sequence of a single mouse imaged every 8 min for a
total of 64 min 共eight images total兲, with 共a兲 the fluorescence from
EGF-labeled with IRDye800CW and 共b兲 with fluorescence from
IRDye700DX. Then the calculated image of binding K23 is shown in
共c兲 as a color plot with units of s−1. 共Color online only.兲

allowed sequential imaging of the mice with 685- and
785-nm excitation, and filtering above 700 and 800 nm, respectively. The temporal sequence of images from one mouse
is shown in Fig. 2共a兲 for EGF-IRDye800 and Fig. 2共b兲 for
IRDye700, with images subscripted 1 through 8 being at approximately 8-min intervals. These images were then processed with each pixel put into Eq. 共10兲, and the resulting K23
image is shown in Fig. 2共c兲. The procedure was repeated for
animals with the two agents 共1兲 EGF-IRDye800 and
IRDye700, and then mice with just nontargeted agents 共2兲
IRDye800 and IRDye700. This latter group was to control for
nonspecific binding of the dye. Calculated images of K23 are
shown in Fig. 3共a兲 for two targeted agent mice in the first
group 共1兲 and two control mice in the second group 共2兲. The
images are displayed in color-coded intensity and overlaid on
the fluorescence image of IRDye700 at longer times to help
visualize. It is readily seen that the binding rate values in the
pancreas range from 3 ⫻ 10−5 to 8 ⫻ 10−5 s−1, and the

AsPC-1 tumor values range from 2 ⫻ 10−5 to 5 ⫻ 10−5 s−1.
Summary whole tissue values are shown in Fig. 3共c兲. Interestingly, this summary data confirms that the binding rate of the
pancreas is higher than that of the tumor, as was expected
from ex vivo analysis.
The value of being able to noninvasively image the binding rate is apparent from these images, in that the normal
pancreas surrounding the tumor actually has a higher binding
rate than the tumor tissue; yet in vivo biopsy of normal tissue
is rarely done, and so this type of imaging may be critical to
determine when biologically targeted therapy is appropriate.
The studies by Durkin et al.5 indicate there is wide variability
in EGFR expression in pancreas tumor lines and an unknown
level in normal pancreas. The secondary value of the algorithm presented here is to allow accurate quantification of the
effective binding rate in vivo, which can be quantitatively
compared to ex vivo data. This will be important as new therapeutics and molecular contrast agents are developed. Perhaps
the only caution in applying this numerical approach is a careful interpretation of the assumptions going into the final equation. The most inaccurate assumption for tumor imaging
would be the assumption that v1C1共t兲 Ⰶ v2C2共t兲 + v3C3共t兲,
which is usually true in normal tissue but can be violated if
there are areas of blood pooling. Thus it will be important to
consider elimination of estimates of K23 in these type of regions. Finally, it is important to recognize that this dual-agent
imaging approach might also be extendable to other imaging
modalities where double injection is feasible, through spectroscopic separation 共as was done here兲, or through sequential
imaging exams.
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Fig. 3 Calculated images of K23 in color, for 共a兲 two mice with EGF
targeted dye and 共b兲 two mice with only the control dye without EGF.
The images are overlaid on the intensity fluorescence images to allow
visualization of binding rates in the pancreas 共white arrow兲 and tumor
共black arrow兲 regions. The color bar units are s−1. The summary of
values for tumor, pancreas, and muscle is shown in 共c兲 for the EGF
and control dyes alone. 共Color online only.兲
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